Director, New Product Planning
Director, New Product Planning
Candidates should be located in Denver, Bay Area, Los Angeles (SoCal), or Seattle.
Job Description
We are a fast-growing and dynamic organization seeking a Director, New Product Planning to join our team. This role is a commercial leader responsible for shaping the direction and commercialization of the company's pipeline and future growth portfolio. Serving as a critical bridge between the marketplace and enterprise leadership, this role drives customer-centric strategy through deep engagement with healthcare stakeholders, key opinion leaders (KOLs), health systems, payers, patients, and industry influencers.
The Director leads the generation and integration of market insights that inform portfolio prioritization, clinical development strategy, business development decisions, and commercialization planning. This position influences key investment decisions and ensures that customer, market, and competitive perspectives are embedded throughout the product lifecycle.
Working across Commercial, Medical Affairs, Clinical Development, Market Access, Regulatory and Business Development, the Director provides leadership for pipeline assets from early development through launch readiness while helping shape the organization's long-term growth strategy.
_Good things are happening at Omeros!_
_Who is Omeros?_
Omeros is an innovative biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for both large-market and orphan indications, with a focus on complement-mediated diseases, cancers, and addictive or compulsive disorders. Omeros’ lead complement inhibitor YARTEMLEA® (narsoplimab-wuug), which targets the lectin pathway’s effector enzyme MASP-2, is FDA-approved and commercially available in the U.S. for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) in adult and pediatric patients aged two years and older. OMS1029, Omeros’ long-acting MASP-2 inhibitor, has successfully completed Phase 1 clinical trials.
Under a recently announced asset purchase and licensing agreement, Novo Nordisk acquired global rights to zaltenibart (formerly OMS906), an inhibitor of MASP-3, the alternative pathway’s key activator, which is in clinical development for PNH and other alternative pathway indications, along with associated intellectual property and related assets. Omeros’ pipeline also includes OMS527, a phosphodiesterase 7 inhibitor in clinical development for cocaine use disorder, which is fully funded by the National Institute on Drug Abuse, and a growing portfolio of novel recombinant antibodies targeting multidrug-resistant organism...
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.
Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam, eaque ipsa quae ab illo inventore veritatis.